Diabetes Digital Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 2.1 billion
Estimated Base Value
2035 Forecast
US$ 12.1 billion
Projected Market Value
CAGR 2026–2035
19.1%
Compound Annual Growth
Largest Segment
Prescription Digital Therapeutics
Fastest Growing Segment
Digital Diabetes Management Platforms
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
42.5% market share
Key Players
Virta Health
Emerging Players
BeatO, Holmusk
Market Definition & Overview
The Diabetes Digital Therapeutics Market encompasses software-driven interventions and platforms designed to prevent, manage, or treat diabetes and its related complications. These evidence-based digital solutions, often delivered via mobile applications, web platforms, or integrated with connected devices, aim to modify patient behavior, improve medication adherence, optimize glucose control, and provide personalized coaching and education. This market specifically covers clinically validated programs targeting Type 1, Type 2, prediabetes, and gestational diabetes, focusing on improving health outcomes through digital means within the broader digital medicine and healthcare services industry.
Scope
- Global coverage, with detailed analysis for major regions including North America, Europe, and Asia Pacific
- Segmentation by diabetes type (Type 1, Type 2, Prediabetes), product type (prescription vs. non-prescription), and end-user
- Analysis period covering historical data, current market estimates, and a five-to-seven-year forecast
Inclusions
- Prescription Digital Therapeutics (PDT) specifically for diabetes management
- Mobile applications offering behavioral change programs and glucose monitoring for diabetes
- Web-based platforms providing personalized diabetes coaching and education
- Integrated digital programs facilitating medication adherence and insulin dosage adjustments
- Connected devices (e.g., smart glucose meters) with integrated digital therapeutic components
- AI-driven algorithms for personalized insights and recommendations in diabetes care
Exclusions
- Traditional medical devices for diabetes (e.g., standalone insulin pumps, BGM devices) without digital therapeutic integration
- General health and wellness applications not specifically tailored for diabetes management
- Telehealth services focused purely on virtual doctor consultations without a structured digital therapeutic program
- Pharmaceutical drugs or insulins for diabetes treatment
- Hospital or clinic-specific Electronic Health Records (EHR) systems
Market Size Forecast
Executive Summary
• The Diabetes Digital Therapeutics market is valued at $2.1 Bn in 2025 and is forecast to reach $12.1 Bn by 2035, reflecting a robust CAGR of 19.1% as demand accelerates across every major segment and region over the ten-year outlook.
• Prescription Digital Therapeutics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 15.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 42.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intense competitive dynamics are fueling strategic partnerships and M&A, as established healthcare players and tech giants vie for market leadership in integrated diabetes management platforms.
• The accelerating shift towards value-based care models, coupled with increasing chronic disease prevalence and remote patient monitoring mandates, represents a powerful catalyst for DDT adoption globally.
• Advanced AI and machine learning integration, alongside evolving regulatory frameworks and clearer reimbursement pathways, are rapidly accelerating the clinical validation and market penetration of sophisticated DDT solutions.
• While North America remains the primary adoption hub, significant growth is anticipated across European and APAC markets, driven by increasing Type 2 diabetes prevalence and localized digital health infrastructure investments.
• Sustained robust venture capital and strategic corporate investments are fostering continuous innovation, particularly in predictive analytics and personalized intervention, crucial for long-term supply chain resilience and market leadership.
• The market is poised for a significant evolution towards integrated chronic care platforms, moving beyond standalone solutions to offer holistic, preventative, and personalized diabetes management across diverse patient populations.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Diabetes Digital Therapeutics Market was valued at $5.9 billion in the base year.
Projected Market Surge
The market is projected to reach a substantial $36.8 billion by the forecast year.
High Growth Trajectory
This expansion signifies an impressive Compound Annual Growth Rate (CAGR) of 20.1% over the forecast period.
Exponential Market Growth
From a $5.9 billion valuation in the base year, the market is expected to achieve a significant $36.8 billion by the forecast year.
North American Dominance
North America is anticipated to maintain its leadership position due to high adoption rates of digital health solutions and substantial healthcare expenditure.
Personalized Care Adoption
A notable trend driving market expansion is the increasing demand for personalized digital therapeutics leveraging AI for tailored diabetes management.
Market Dynamics
Market Trends
- Rising adoption of AI and machine learning for personalized diabetes care.
- Increased shift towards remote patient monitoring and virtual care solutions.
- Growing integration of wearables and IoT devices for continuous data.
- Emphasis on holistic health and behavioral change programs.
Growth Drivers
- Increasing global prevalence of both Type 1 and Type 2 diabetes.
- High costs of traditional diabetes management are pushing digital solutions.
- Growing demand for convenient, accessible, and personalized care.
- Rapid technological advancements in mobile health and data analytics.
Restraints
- Reimbursement challenges limit market adoption and widespread access.
- Ensuring long-term patient engagement and adherence remains difficult.
- Complex regulatory pathways hinder rapid product development and launch.
- Data privacy and security concerns deter widespread user trust.
Opportunities
- Expansion into new geographic markets and underserved patient segments.
- Development of specialized solutions for specific diabetes types or comorbidities.
- Integration with broader healthcare systems and electronic health records.
- Focus on pre-diabetes management and prevention programs.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Prescription Digital TherapeuticsNon-Prescription Digital TherapeuticsDigital Diabetes Management PlatformsDigital Coaching & Engagement PlatformsRemote Monitoring & Alert Systems |
| By Application | Type 1 Diabetes ManagementType 2 Diabetes ManagementPre-Diabetes Management & PreventionGestational Diabetes ManagementDiabetes Complications ManagementInsulin Titration & Dosing SupportWeight Management for Diabetes |
| By Technology | Artificial Intelligence & Machine LearningCloud-Based PlatformsMobile ApplicationsWearable & Sensor Technology IntegrationData Analytics & Visualization ToolsGamification & Behavioral ScienceSecure Communication & Interoperability Solutions |
| By End-User | Patients & CaregiversHospitals & ClinicsEmployers & PayersPharmaceutical & Medical Device CompaniesIndividual Healthcare Providers |
| By Deployment | Cloud-Based Software as a ServiceOn-Premise SoftwareHybrid Cloud |
| By Functionality | Glucose Monitoring & TrackingMedication & Insulin ManagementBehavioral & Lifestyle CoachingEducational & Self-Management ToolsRemote Patient Monitoring & AlertsPersonalized Feedback & GamificationData Analytics & ReportingInteroperability With Electronic Health Records |
Regional Analysis
- North America leads the diabetes digital therapeutics market due to high diabetes prevalence, significant healthcare expenditure, and advanced technological infrastructure. Favorable reimbursement policies and strong consumer adoption of digital health solutions further drive its dominance in this sector.
- Asia-Pacific is the fastest-growing region, driven by its vast population, increasing diabetes incidence, and improving digital health literacy. Government initiatives promoting digital healthcare and rising disposable incomes are fueling rapid market expansion here.
- In Europe, a significant trend is the increasing focus on regulatory clarity and reimbursement pathways for digital therapeutics, particularly under new MDR regulations. This is fostering greater market access and adoption, making real-world evidence crucial for success.
Asia Pacific
12.5% CAGR
$462.0 Mn
22% share
- Witnessing rapid growth fueled by a large diabetic population, improving digital literacy, and government initiatives aimed at expanding access to advanced healthcare solutions across diverse geographies.
North America
9.0% CAGR
$798.0 Mn
38% share
- This region leads the market due to robust healthcare infrastructure, high technology adoption rates, and significant investments in digital health innovation and R&D for diabetes management.
Europe
8.5% CAGR
$588.0 Mn
28% share
- A mature market driven by strong public healthcare systems and increasing regulatory frameworks supporting digital therapeutics, despite some challenges from fragmented national healthcare policies.
Latin America
11.0% CAGR
$126.0 Mn
6% share
- An emerging market with increasing awareness and adoption of digital therapeutics, driven by efforts to enhance chronic disease management and bridge healthcare access gaps in underserved areas.
Middle East & Africa
10.5% CAGR
$84.0 Mn
4% share
- This region is experiencing nascent but promising growth, particularly in Gulf Cooperation Council (GCC) countries, as governments prioritize healthcare digitalization and innovation.
Emerging Areas
15.0% CAGR
$42.0 Mn
2% share
- Representing smaller, nascent geographies, this market holds significant untapped potential, characterized by increasing mobile penetration and a growing demand for scalable and accessible healthcare solutions.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $892.5 Mn | 11.8% | The largest market for digital therapeutics, driven by high diabetes prevalence, significant healthcare expenditure, and a strong innovation ecosystem for digital health solutions. Regulatory frameworks like FDA clearances also accelerate adoption. |
| 2 | Brazil | $48.3 Mn | 17.5% | A key market in Latin America due to its large population and high diabetes burden. Increasing internet and smartphone penetration, combined with a demand for accessible healthcare, fuels the growth of digital diabetes solutions. |
| 3 | Germany | $178.5 Mn | 11.2% | A pioneering market with its DiGA framework allowing for digital health apps to be prescribed and reimbursed, significantly boosting the adoption and integration of diabetes digital therapeutics into mainstream care. |
| 4 | China | $193.2 Mn | 19.8% | Represents the largest market in Asia-Pacific due to its immense population, high and growing diabetes burden, and aggressive government support for digital healthcare innovation. Telemedicine and digital health platforms are rapidly expanding. |
| 5 | Saudi Arabia | $25.2 Mn | 17.0% | Driven by a high prevalence of diabetes and ambitious national digital transformation initiatives like Vision 2030, which emphasize health technology adoption. Significant government investment in healthcare infrastructure further boosts market growth. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Virta Health | 5.7% | Focus on reversing type 2 diabetes and other metabolic conditions through a physician-supervised, low-carbohydrate ketogenic therapy. | It is widely recognized for its clinical studies demonstrating high rates of type 2 diabetes remission and medication deprescription. | Continues to expand its partnerships with major health plans and large self-insured employers, increasing access to its diabetes reversal program. | Virta TreatmentVirta for Type 2 DiabetesVirta for Prediabetes+1 |
| 2 | Omada Health | 5.4% | Provide integrated virtual care programs for a broad spectrum of chronic conditions, leveraging a coaching-first approach and a holistic health model. | One of the most established and broadly adopted digital health companies, known for its comprehensive platform addressing multiple comorbidities. | Consistently expands its chronic condition offerings and integrates behavioral health support across its entire platform. | Omada Program for DiabetesOmada Program for PrediabetesOmada Program for Hypertension+1 |
| 3 | One Drop | 5.1% | Empower individuals with chronic conditions through AI-powered personalized insights, human coaching, and connected health devices. | Distinguished by its user-friendly design, integrated hardware, and advanced AI for predictive health analytics. | Focuses on enhancing its AI engine for more precise health predictions and integrating with a wider range of health data sources. | One Drop PremiumOne Drop ProfessionalAI-powered health predictions+1 |
| 4 | DarioHealth | 4.9% | Offer a full-spectrum, multi-chronic condition platform providing personalized digital therapeutics and connected devices for a 'whole person' approach. | Known for its integrated platform that supports management of multiple chronic conditions simultaneously, including behavioral health. | Actively pursues strategic acquisitions, such as Twill (formerly Happify Health), to expand its clinical capabilities and market reach. | Dario AppDario Blood Glucose Monitoring SystemDario Diabetes Program+1 |
| 5 | Glooko | 4.6% | Provide a universal platform for diabetes data management, integrating data from a wide array of devices for patients and clinicians globally. | A global leader in diabetes data management, compatible with over 95% of diabetes devices worldwide. | Continuously expands its global footprint and integrates with new diabetes devices and electronic health record systems. | Glooko PlatformDiasend by GlookoGlooko Mobile App+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Virta Health, Omada Health, One Drop, DarioHealth, Glooko, Twin Health, WellDoc, Better Therapeutics, Noom, Vida Health, Lark Health, Oviva, Liva Healthcare, Day Two, HealthifyMe, NutriSense, Levels Health, Signos, AmDTx, Hedia
The global Diabetes Digital Therapeutics market features a competitive landscape led by Virta Health, Omada Health, One Drop, DarioHealth, Glooko, and Twin Health, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Virta Health
Omada Health
One Drop
DarioHealth
Glooko
Twin Health
WellDoc
Better Therapeutics
Noom
Vida Health
Lark Health
Oviva
Liva Healthcare
Day Two
HealthifyMe
NutriSense
Levels Health
Signos
AmDTx
Hedia
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Omada Health and Dexcom Announce Enhanced CGM Integration for Diabetes Management
Digital health leader Omada Health has expanded its strategic partnership with Dexcom, allowing for real-time integration of continuous glucose monitoring data directly into Omada's personalized diabetes management platform. This collaboration aims to provide users and coaches with more immediate and actionable insights, optimizing treatment plans and improving glycemic control.
Teladoc Health Unveils AI-Powered Predictive Insights for Livongo Diabetes Program
Teladoc Health has launched new AI-driven predictive analytics within its Livongo for Diabetes program, designed to anticipate potential health risks and provide proactive, personalized interventions. The new feature leverages machine learning to analyze member data, offering timely recommendations and coaching support to prevent complications.
Virta Health Secures Broader Payer Coverage Following Clinical Efficacy Studies
Virta Health announced significant progress in market access, securing new agreements with major health plans to expand coverage for its diabetes reversal program. This follows published clinical data further demonstrating the program's long-term efficacy in reducing medication dependence and improving health outcomes for type 2 diabetes patients.
DarioHealth Closes Strategic Funding Round to Accelerate Platform Expansion
DarioHealth, a prominent provider of digital therapeutics for chronic conditions including diabetes, announced the completion of a strategic funding round led by new institutional investors. The capital infusion is earmarked to accelerate product development, expand its multi-condition platform, and grow its market presence across employer and payer channels.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $2.1 Bn |
| Market Size (Forecast) | $12.1 Bn |
| CAGR | 19.1% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 35 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included